Please assess the completion status of the following clinical trial:

Trial Title: Light, Ion, and Fluoxetine Efficacy (LIFE) in Depression

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female outpatients aged 19-60 years.~* Patients will meet DSM-IV criteria for major depressive disorder as determined by the mood disorders section of the Mini International Neuropsychiatric Interview (MINI, Sheehan et al, 1998).~* A score of 20 or greater on the Hamilton Depression Rating Scale (Ham-D), indicating at least moderately severe depression.~* Competency to give informed consent.~Exclusion Criteria:~* Pregnant women, lactating women and sexually active women of childbearing potential who are not using medically accepted means of contraception.~* Serious suicidal risks as judged by the clinician and the MINI.~* The following DSM-IV diagnoses (to ensure a homogeneous diagnostic group): organic mental disorders; substance abuse/dependence, including alcohol, active within the last year; schizophrenia, paranoid, or delusional disorders; other psychotic disorders; panic disorder or generalized anxiety disorder, if a primary diagnosis; obsessive-compulsive disorder or post-traumatic stress disorder; bipolar disorder; bulimia nervosa or anorexia nervosa.~* Serious illness including cardiac, hepatic, renal, respiratory, endocrinologic, neurologic and hematologic disease that is not stabilized, or a past history of convulsions.~* Any retinal disease or systemic illness with active retinal involvement (e.g. diabetes) that precludes the use of bright light.~* Patients who have a history of severe allergies and multiple drug adverse reactions.~* Regular or current use of other psychotropic drugs, including lithium and tryptophan.~* Patients treated with beta blocking drugs.~* Hypertensive patients being treated with guanethidine, reserpine, clonidine or methyldopa (because of possible mood-altering effects of those drugs).~* Use of monoamine oxidase inhibitors within 14 days of Visit 1 (to ensure no drug interactions between fluoxetine and MAOIs), or use of heterocyclic antidepressants within 7 days of Visit 1 (to ensure adequate washout period of two weeks between stopping previous drug and start of treatment at Visit 2).~* Previous use of fluoxetine or light therapy.~* Treatment resistance in the current episode, as defined by failure (lack of clinically significant response) of two or more antidepressants given at therapeutic doses for at least 6 weeks.~* Patients who start formal psychotherapy (e.g. cognitive-behavioural or interpersonal psychotherapy) within 3 months of Visit 1, or who plan to initiate such psychotherapy during this study.~* Patients involved in any other form of treatment for depression.

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Light treatment using a fluorescent light box (30 minutes daily) plus a placebo pill every day
- 2 (Type: EXPERIMENTAL): Negative ion generator (30 minutes daily) plus 20 mg of fluoxetine per day
- 3 (Type: ACTIVE_COMPARATOR): Light treatment using a fluorescent light box (30 minutes daily) plus 20 mg of fluoxetine per day
- 4 (Type: PLACEBO_COMPARATOR): Negative ion generator (30 minutes daily) plus placebo pill every day

Based on this trial design, predict the completion outcome and termination type (if applicable).